These findings suggest that targeting this lncRNA combined with the FDA approved SMN2 splice-switching oligonucleotides (Spinraza) could represent a valuable therapeutic approach for severe SMA cases characterized by very low SMN levels (U.S. Food & Drug Administration, 2016; d’Ydewalle et al., 2017). Here, SMN1 is linked to proximal spinal muscular atrophy.